885 West Georgia Street
About Sierra Oncology
Sierra Oncology is a clinical stage drug development company advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer. We are an ambitious company, oriented towards achieving the successful registration and commercialization of our drug candidates and we have a world-class management team with a proven track record of success in oncology drug development.
CEO: Nick Glover
CBO: Angie You
CMO: Mark Kowalski
CFO: Sukhi Jagpal
Please click here for Sierra Oncology job opportunities.
Please click here for clinical trial information.
101 articles with Sierra Oncology
Sareum notes Sierra Oncology has reported its Second Quarter 2019 Results and Published its Form 10-Q with the US SEC
Sareum Holdings PLC, the specialist small molecule drug development business notes that Sierra Oncology, the licence holder advancing clinical cancer candidate SRA737, has announced its financial and operational results for the second quarter 2019 ended 30 June 2019.
Sierra Oncology, Inc. reported its financial and operational results for the second quarter ended June 30, 2019.
Presentation scheduled for 2:30 pm ET on August 14, 2019
Sierra Oncology Launches Campaign Exploring Non-Dilutive Strategic Options to Support Development of its DDR Assets
Sierra Oncology, Inc. announced plans to prioritize its existing resources on the development of momelotinib, its differentiated Phase 3 drug candidate for the treatment of patients with myelofibrosis.
Sierra Oncology, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to momelotinib, a JAK1, JAK2 and ACVR1 inhibitor, for the treatment of patients with intermediate/high-risk myelofibrosis who have previously received a JAK inhibitor.
Sierra Announces FDA Regulatory Clarity for Momelotinib & Design of the MOMENTUM Phase 3 Clinical Trial
Sierra Oncology, Inc. announced that it has obtained regulatory clarity with the U.S. Food and Drug Administration (FDA) concerning the design of a Phase 3 clinical trial for momelotinib intended to support potential registration of this differentiated drug candidate for the treatment of previously JAK inhibitor treated myelofibrosis patients.
Sierra Oncology, Inc. is holding an analyst and investor event featuring distinguished oncologists Professor Johann de Bono and Dr. Rebecca Kristeleit, to discuss clinical findings and possible next steps for its oral, highly selective Chk1 inhibitor, SRA737.
Sierra Announces Promising Preliminary Efficacy in SRA737 Clinical Program & Outlines Potential Path to Registration
Sierra Oncology, Inc. reported positive preliminary clinical data from its two first-in-human Phase 1/2 studies of SRA737, a highly selective oral Chk1 inhibitor, as monotherapy and as SRA737+LDG (SRA737 potentiated by low dose gemcitabine), at the 2019 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.
Sierra Oncology to Present Momelotinib and SRA737 Overview at the Jefferies Global Healthcare Conference in New York
Sierra Oncology, Inc. announced that Dr. Nick Glover, President and Chief Executive Officer, will present an overview of the company and updates concerning its clinical stage drug candidates, momelotinib and SRA737, at 8:00 am ET on Wednesday, June 5 at the Jefferies Global Healthcare Conference being held in New York.
Sierra Oncology, Inc. reported its financial and operational results for the first quarter ended March 31, 2019.
Sierra Oncology, Inc. announced that members of its senior management team will be attending the SunTrust Robinson Humphrey 5th Annual Life Sciences Conference in New York on May 8th, and the Oppenheimer Oncology Insight Summit in New York on May 16th.
Compelling preclinical data for its Cdc7 inhibitor, SRA141, indicate a potentially novel and distinct mechanism of action
Late-breaking oral presentation reports profound, durable synergistic activity for immunotherapy combined with SRA737+LDG, its Chk1 inhibitor plus low dose gemcitabine (LDG), in small cell lung cancer models
Dr. Christian Hassig, CSO, scheduled to present at 10:00 a.m. ET on March 13, 2019
Sierra Oncology, Inc. reported its financial and operational results for the year ended December 31, 2018.
Sierra Oncology Announces Late-Breaking Oral and Poster Presentations at AACR 2019 for SRA737 and SRA141 Preclinical Data
Late-breaking oral presentation to report preclinical mechanistic and efficacy data for immunotherapy combined with SRA737 + LDG, its Chk1 inhibitor plus low dose gemcitabine (LDG), in small cell lung cancer models
"Addressing Intrinsic & Acquired PARP Inhibitor Resistance Through Chk1 Inhibition" scheduled for 9:00 am ET on January 30 in Boston
Sierra Oncology Reports Robust Transfusion Independence Rates in Transfusion Dependent Myelofibrosis Patients Treated with Momelotinib
44% of transfusion dependent myelofibrosis patients (multi-study aggregate N=152) were transfusion free for at least 12 weeks; 49% were transfusion free for at least 8 weeks
Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737
SRA737 synergizes with immune checkpoint blockade in small cell lung cancer (SCLC)
Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development company focused on advancing targeted therapeutics for the treatment of patients with significant unmet needs in hematology and oncology, today announced that it will host an Analyst & Investor call on Monday, December 3rd